Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

Recent Price Movement and Market Context

The stock has been under pressure for the last two consecutive days, losing 7.43% in that period. Today’s intraday low of Rs 469.10 was accompanied by a weighted average price indicating that a larger volume of shares traded near this low, signalling selling pressure. Compared to its sector, Akums underperformed by 4.06% today, reflecting a weaker investor appetite relative to peers. Furthermore, delivery volumes have declined by 14.45% against the five-day average, suggesting reduced investor participation and possibly waning confidence in the short term.

Technically, the stock price remains above its 50-day and 100-day moving averages, which could be seen as a support level. However, it is trading below its 5-day, 20-day, and 200-day moving averages, indicating recent downward momentum and potential resistance at higher levels. Liquidity remains adequate for moderate trade sizes, but the current trend points to cautious investor behaviour.

Fundamental Strengths and Institutional Interest

Despite the recent price weakness, Akums Drugs & Pharmaceuticals exhibits some positive fundamental attributes. The company maintains a low debt-to-equity ratio, effectively zero, which reduces financial risk and interest burden. Its return on equity (ROE) stands at 9.7%, which, while modest, is accompanied by an attractive valuation with a price-to-book value of 2.3. Notably, the company’s profits have surged by an impressive 1362% over the past year, a remarkable growth figure that contrasts with the stock’s negative return of 8.02% during the same period.

Institutional investors have shown increasing confidence, raising their stake by 4% in the previous quarter to collectively hold 15.55% of the company. This growing institutional participation often signals a belief in the company’s long-term prospects, given their superior analytical resources compared to retail investors.

Challenges Weighing on the Stock

However, several factors are contributing to the stock’s underperformance and recent decline. The company’s ROE of 9.7% is considered low, indicating limited profitability relative to shareholders’ equity. This suggests that management efficiency in generating returns is suboptimal. Additionally, long-term growth metrics reveal modest expansion, with net sales increasing at an annual rate of just 6.10% and operating profit growing at 17.54% over the last five years. Such growth rates may not be sufficient to excite investors seeking robust expansion.

Moreover, the company reported flat results in December 2025, with interest expenses for the nine-month period rising sharply by 225.36% to Rs 70.18 crores. This significant increase in interest costs could be a concern for profitability and cash flow going forward.

From a market perspective, Akums has underperformed the broader market indices. While the BSE500 index generated returns of 5.44% over the past year, Akums’ stock declined by 8.02%, reflecting investor preference for other opportunities within the pharmaceutical sector or broader market.

Conclusion: Balancing Growth Potential Against Market Realities

Akums Drugs & Pharmaceuticals Ltd’s recent share price decline reflects a combination of short-term selling pressure, cautious investor sentiment, and fundamental concerns despite strong profit growth. The stock’s underperformance relative to the market and sector, coupled with rising interest expenses and modest long-term sales growth, have weighed on investor confidence. While institutional investors have increased their holdings, signalling some faith in the company’s prospects, the low ROE and flat recent results suggest management efficiency and growth remain areas for improvement.

Investors considering Akums should weigh its attractive valuation and profit surge against these challenges and the current technical weakness. The stock’s liquidity and support from institutional participation offer some positives, but the recent price action indicates a need for caution amid mixed signals.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →